Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Janux Therapeutics宣佈完成股票和預付認購權證的公開發行，包括承銷商購買額外股份的選項完全行使，總毛收入爲40250萬美元。
